偉星新材(002372.SZ):以200萬美元設立新加坡子公司 作為海外投資控股平台和海外貿易平台
格隆匯 3 月 10日丨偉星新材(002372.SZ)公佈,因戰略規劃與業務發展需要,公司以自有資金200萬美元在新加坡投資設立全資子公司(“新加坡子公司”)。
新加坡子公司於近日完成了相關注冊登記手續,取得新加坡會計與企業管理局(ACRA)頒發的公司註冊證書。
公司此次在新加坡投資設立全資子公司主要基於公司國際化戰略佈局的考慮,公司計劃將其作為海外投資控股平台和海外貿易平台,希望充分利用新加坡在國際金融和國際貿易等方面的優勢,進一步加強國際合作與貿易,以提高公司核心競爭力,加快推進公司國際化進程。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.